| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S1471-4914(02)02307-9 |
| P8608 | Fatcat ID | release_owyhyktnffe2dkl3ohz3ong3je |
| P698 | PubMed publication ID | 11927284 |
| P2093 | author name string | Judith S Sebolt-Leopold | |
| Roman Herrera | |||
| P2860 | cites work | The Hallmarks of Cancer | Q221226 |
| Rsk1 mediates a MEK-MAP kinase cell survival signal | Q22253213 | ||
| Endothelial apoptosis in Braf-deficient mice | Q24314857 | ||
| Raf-1 promotes cell survival by antagonizing apoptosis signal-regulating kinase 1 through a MEK-ERK independent mechanism | Q24633458 | ||
| Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms | Q28137802 | ||
| Phosphorylation and regulation of Raf by Akt (protein kinase B) | Q28138863 | ||
| Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo | Q28368373 | ||
| Signaling from Ras to Rac and beyond: not just a matter of GEFs | Q33931717 | ||
| The Raf signal transduction cascade as a target for chemotherapeutic intervention in growth factor-responsive tumors | Q34241295 | ||
| Absence of the CAAX endoprotease Rce1: effects on cell growth and transformation | Q34290291 | ||
| Discovery of a novel Raf kinase inhibitor | Q34376383 | ||
| Current status of clinical trials of farnesyltransferase inhibitors. | Q34416840 | ||
| Evolving therapies: farnesyltransferase inhibitors | Q34457426 | ||
| Farnesyltransferase inhibitors: mechanism and applications | Q34481874 | ||
| Serum- and glucocorticoid-inducible kinase SGK phosphorylates and negatively regulates B-Raf | Q34515800 | ||
| Biomarker assays for phosphorylated MAP kinase. Their utility for measurement of MEK inhibition | Q35112854 | ||
| Raf induces NF-kappaB by membrane shuttle kinase MEKK1, a signaling pathway critical for transformation | Q35688302 | ||
| Abrogation of c-Raf expression induces apoptosis in tumor cells. | Q38337664 | ||
| Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts | Q42831499 | ||
| Uncoupling Raf1 from MEK1/2 impairs only a subset of cellular responses to Raf activation | Q42835325 | ||
| Measurement of MAP kinase activation by flow cytometry using phospho-specific antibodies to MEK and ERK: potential for pharmacodynamic monitoring of signal transduction inhibitors. | Q43579976 | ||
| Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial | Q43615357 | ||
| Drugs targeted against protein kinases | Q46576613 | ||
| Independent control of cell survival by Raf-1 and Bcl-2 at the mitochondria | Q74421259 | ||
| P433 | issue | 4 Suppl | |
| P921 | main subject | pharmacology | Q128406 |
| P304 | page(s) | S27-31 | |
| P577 | publication date | 2002-01-01 | |
| P1433 | published in | Trends in Molecular Medicine | Q15265842 |
| P1476 | title | Unraveling the complexities of the Raf/MAP kinase pathway for pharmacological intervention | |
| P478 | volume | 8 |
| Q34768386 | A role for K-ras in conferring resistance to the MEK inhibitor, CI-1040. |
| Q44313680 | C-Raf controlled pathways in the protection of tumor cells from apoptosis |
| Q34473579 | Characterization of an ERK-binding domain in microphthalmia-associated transcription factor and differential inhibition of ERK2-mediated substrate phosphorylation |
| Q35577444 | Drug resistance reversal--are we getting closer? |
| Q35730802 | Feedback regulation of lymphocyte signalling |
| Q24802613 | Finding the needle in the haystack: why high-throughput screening is good for your health |
| Q28648013 | Identification of Raf-1 S471 as a novel phosphorylation site critical for Raf-1 and B-Raf kinase activities and for MEK binding |
| Q40364273 | Identification of inhibitors of the kinase activity of oncogenic V600E BRAF in an enzyme cascade high-throughput screen |
| Q34407252 | Identification of novel in vivo Raf-1 phosphorylation sites mediating positive feedback Raf-1 regulation by extracellular signal-regulated kinase |
| Q28543407 | In vitro and in vivo antitumor activity of a novel semisynthetic derivative of cucurbitacin B |
| Q44403188 | Inhibition of the MEK/ERK pathway has no effect on agonist-induced aggregation of human platelets |
| Q46514063 | MEK hyperphosphorylation coincides with cell cycle shut down of cultured smooth muscle cells |
| Q40455851 | MEK-ERK signaling controls Hdm2 oncoprotein expression by regulating hdm2 mRNA export to the cytoplasm. |
| Q35023644 | Mitogen activated protein (MAP) kinase signal transduction pathways and novel anti-inflammatory targets. |
| Q40290658 | Mogrol represents a novel leukemia therapeutic, via ERK and STAT3 inhibition. |
| Q30433431 | Molecular genesis of non-muscle-invasive urothelial carcinoma (NMIUC) |
| Q36103287 | Oncogenic Ras in tumour progression and metastasis |
| Q36812355 | Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies |
| Q28278381 | Pharmacodynamic biomarkers for molecular cancer therapeutics |
| Q21245746 | Phospholipase C delta-4 overexpression upregulates ErbB1/2 expression, Erk signaling pathway, and proliferation in MCF-7 cells |
| Q37181827 | Protein and lipid kinase inhibitors as targeted anticancer agents of the Ras/Raf/MEK and PI3K/PKB pathways |
| Q35147439 | Raf kinases in lung tumor development |
| Q36002845 | Raf kinases: function, regulation and role in human cancer |
| Q33869194 | Spotlight on differentially expressed genes in urinary bladder cancer. |
| Q50335943 | Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition |
| Q35968411 | Targeting the mitogen-activated protein kinase cascade to treat cancer |
| Q40640417 | The MEK/ERK pathway acts upstream of NF kappa B1 (p50) homodimer activity and Bcl-2 expression in a murine B-cell lymphoma cell line. MEK inhibition restores radiation-induced apoptosis |
| Q34804764 | The RB and p53 pathways in cancer |
| Q35919391 | The transcriptional response to Raf activation is almost completely dependent on Mitogen-activated Protein Kinase Kinase activity and shows a major autocrine component |
| Q40620732 | Transforming Growth Factor β1 Is Up-regulated by Activated Raf in Skeletal Myoblasts but Does Not Contribute to the Differentiation-defective Phenotype |
| Q24797025 | Use of mitogenic cascade blockers for treatment of C-Raf induced lung adenoma in vivo: CI-1040 strongly reduces growth and improves lung structure |
| Q30847612 | p42/p44 MAPKs are intracellular targets of the CDK inhibitor purvalanol |
Search more.